E-LIB Suche - Ergebnisse für: Rejeski K

1

Modification of Lugano Criteria by Pre‐Infusion Tumor Kinet..:

Kunz, W. G. ; Blumenberg, V. ; Rejeski, K....
Hematological Oncology. 41 (2023) S2 - p. 347-348 , 2023

Link: https://doi.org/10.1002/..

2

P06.11.B NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECOND..:

Karschnia, P ; Arrillaga-Romany, I C ; Eichler, A...
Neuro-Oncology. 25 (2023) Supplement_2 - p. ii47-ii48 , 2023

Link: https://doi.org/10.1093/..

3

SEVERE HEMATOLOGICAL TOXICITY FOLLOWING CD19 CAR‐T FOR RELA..:

Rejeski, K. ; Perez, A. ; Iacoboni, G....
Hematological Oncology. 41 (2023) S2 - p. 204-204 , 2023

Link: https://doi.org/10.1002/..

4

Reasons for Discordance Among Imaging‐based Response Criter..:

Winkelmann, M. ; Blumenberg, V. ; Rejeski, K....
Hematological Oncology. 41 (2023) S2 - p. 529-530 , 2023

Link: https://doi.org/10.1002/..

5

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT ..:

Rejeski, K. ; Albanyan, O. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 1340-1341 , 2022

Link: https://doi.org/10.1097/..

6

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR ..:

Blumenberg, V. ; Siegmund, L. ; Frölich, L....
HemaSphere. 6 (2022) - p. 1328-1329 , 2022

Link: https://doi.org/10.1097/..

7

P1438: PROCALCITONIN IS ELEVATED IN SEVERE INFECTIONS AFTER..:

Rejeski, K. ; Blumenberg, V. ; Hildebrand, F....
HemaSphere. 6 (2022) - p. 1321-1322 , 2022

Link: https://doi.org/10.1097/..

8

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSE..:

Bücklein, V. ; Perez, A. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 1330-1331 , 2022

Link: https://doi.org/10.1097/..

9

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION ..:

Frölich, L. ; Blumenberg, V. ; Rejeski, K....
HemaSphere. 6 (2022) - p. 2080-2081 , 2022

Link: https://doi.org/10.1097/..

10

CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATE..:

Rejeski, K. ; Perez, A. ; Sesques, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐F..:

Bücklein, V. ; Blumenberg, V. ; Ackermann, J....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

22 MUTATIONS IN SRSF2 IDENTIFIED IN MYELODYSPLASIA AFFECT R..:

Liang, Y. ; Daubner, G. ; Tebaldi, T....
Leukemia Research. 39 (2015) - p. S9-S10 , 2015

Link: https://doi.org/10.1016/..

13

Inferior outcomes of EU versus US patients treated with CD1..:

Bücklein, V ; Perez, A ; Rejeski, K...
http://edoc.mdc-berlin.de/23596/1/23596oa.pdf. , 2023

Link: http://edoc.mdc-berlin.d..

14

Immune effector cell-associated hematotoxicity (ICAHT): EHA..:

Rejeski, K ; Subklewe, M ; Aljurf, M...
https://eprints.whiterose.ac.uk/200638/1/Rejeski%20et%20al%20ICAHT%20Blood%202023.pdf. , 2023

Link: https://eprints.whiteros..

15

Severe hematotoxicity after CD19 CAR-T therapy is associate..:

Rejeski, K ; Perez, A ; Iacoboni, G...
http://edoc.mdc-berlin.de/23746/1/23746oa.pdf. , 2023

Link: http://edoc.mdc-berlin.d..